- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04048369
Impact of Influenza/RSV PCR Point-of-care Testing in the Emergency Medical Service.
Impact Study of a Rapid Diagnosis of Influenza in the Emergency Medical Service During the 2018-2019 Epidemic Season
The purpose of the study is to compare Emergency Department patients who undergo influenza and RSV PCR testing using an FDA-approved point-of-care device (Cepheid Xpert® Xpress Flu/RSV) located in the ED, to patients who undergo influenza and RSV PCR testing at the core laboratory.
The principal purpose is to determine if the time spent in the ED is different in the group undergoing POC influenza testing compared to those undergoing laboratory-based influenza testing.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- This study will be conducted during the influenza's epidemic season. The start and the end of this study will be determined using national epidemic bases (national reference center for inluenza in Lyon).
- Collection of consent of eligible patients after medical information by a senior emergency physician
- Sampling = nasopharyngeal swabbing for all patients using usual testing or point-of-care testing
- first arm : performing the test at the adult emergency department 24h/24
- second arm : sending the test to the virology laboratory and realization during working hours
- Collection of clinical data : a specific standardized questionnaire is used, as soon as the patient is included and until he leaves the emergency medical service, to collect clinical data and the time taken to take care of the patient
In order to reduce the bias of this study, it has been established :
After verification of the eligibility criteria and obtaining the written consent of the patient, a randomization procedure will be initiated for the patient. Randomization will be centralized at the DRCI of Clermont-Ferrand University Hospital. Patients will be randomly assigned to one of the study groups by means of individual block randomization. A document describing the randomization procedure will be kept confidentially in the DRCI of Clermont-Ferrand University Hospital;
- The collection of data will be prospective.
A listing of patients opposing to the study's participation to verify that their characteristics are homogeneous to the general population The choice of the Genexpert® automaton used in the "point of care testing" arm whose principle of operation requires a minimum of manipulations (<2 minutes) and does not generate inter-operator variability Statistical analyzes will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at the risk of error of the first species α of 5%. Part of the analysis of the secondary endpoints should be primarily exploratory in nature. As discussed by Feise in 2002 (Feise RJ, Do 2: 8), the adjustment of the risk of error of 1st species will not be proposed systematically, but case by case in view of clinical considerations and not just statistical ones.
Continuous variables will be presented as mean and standard deviation, subject to the normality of their distribution (Shapiro-Wilk test if necessary). In case of non-normality, they will be presented as median, quartiles, and extreme values. The qualitative variables will be expressed in numbers and percentages associated. Graphic representations will be associated with these analyzes as much as possible.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Auvergne
-
Clermont-Ferrand, Auvergne, France, 63003
- CHU de Clermont-Ferrand
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria :
- 18 years old and older
- coming in the emergency medical service
- during the influenza epidemic period
- with influenza symptoms
- whose support requires virologic confirmation
- people having given their consent
Exclusion criteria :
- pregnant or breast feeding women
- patient unable to give consent
- tutorship or curatorship or under the protection of justice
- patient non registered in the social security system
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Point-of-care testing arm
for patients randomized to the Point-of-care testing arm, nurse will perform influenza and RSV testing using an FDA-approved point-of-care device (Cepheid Xpert® Xpress Flu/RSV) in the ED, 24/24, 7/7.
|
Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).
|
Active Comparator: Core Lab testing arm
for patients randomized to the Core lab testing arm, influenza/RSV PCR will be performed in the core virology laboratory using Simplexa Flu A/B and RSV direct (r) assay (Diasorin), during working hours (8 am-6pm Monday to Friday, 8 am-5pm the Saturday)
|
Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time of care in the adult emergency department
Time Frame: through study completion, an average of 1 week
|
Emergency care time, calculated from the time of first medical-care contact to the time of release of the adults emergency department. This time will be calculated from the data collected on the standardized questionnaire |
through study completion, an average of 1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prescription of antibiotics initiated at the adults emergency department
Time Frame: within 72 hours after taking care of the patient
|
nature of antibiotics
|
within 72 hours after taking care of the patient
|
Duration of the prescription of antibiotics initiated at the adults emergency department
Time Frame: within 72 hours after taking care of the patient
|
duration of treatment (day)
|
within 72 hours after taking care of the patient
|
Posology of antibiotics initiated at the adults emergency department
Time Frame: within 72 hours after taking care of the patient
|
posology (mg)
|
within 72 hours after taking care of the patient
|
Costs of antibiotics initiated at the adults emergency department
Time Frame: within 72 hours after taking care of the patient
|
associated costs (euros)
|
within 72 hours after taking care of the patient
|
Prescription of antiviral initiated in adults emergency department
Time Frame: within 72 hours after taking care of the patient
|
nature of antiviral prescription
|
within 72 hours after taking care of the patient
|
Duration of the specific antiviral prescription initiated in adults emergency department
Time Frame: within 72 hours after taking care of the patient
|
duration of treatment (day)
|
within 72 hours after taking care of the patient
|
Costs of specific antiviral prescription initiated in adults emergency department
Time Frame: within 72 hours after taking care of the patient
|
associated costs (euros)
|
within 72 hours after taking care of the patient
|
Type of prescription of imaging tests at the adults emergency department
Time Frame: within 72 hours after taking care of the patient
|
type of examinations related to the patient respiratory pathology
|
within 72 hours after taking care of the patient
|
Number of prescription of imaging tests at the adults emergency department
Time Frame: within 72 hours after taking care of the patient
|
Number of examinations related to the patient respiratory pathology
|
within 72 hours after taking care of the patient
|
Costs of the prescription of imaging tests at the adults emergency department
Time Frame: within 72 hours after taking care of the patient
|
Costs of examinations related to the patient respiratory pathology (euros)
|
within 72 hours after taking care of the patient
|
Type of prescription of biology examinations
Time Frame: within 72 hours after taking care of the patient
|
type of laboratory examinations related to respiratory pathology
|
within 72 hours after taking care of the patient
|
Number of prescription of biology examinations
Time Frame: within 72 hours after taking care of the patient
|
Number of laboratory examinations related to respiratory pathology
|
within 72 hours after taking care of the patient
|
Costs of prescription of biology examinations
Time Frame: within 72 hours after taking care of the patient
|
Costs of laboratory examinations related to respiratory pathology (euros)
|
within 72 hours after taking care of the patient
|
Collaborators and Investigators
Investigators
- Principal Investigator: Cécile Henquell, PU-PH, University Hospital, Clermont-Ferrand
Publications and helpful links
General Publications
- Soto M, Sampietro-Colom L, Vilella A, Pantoja E, Asenjo M, Arjona R, Hurtado JC, Trilla A, Alvarez-Martinez MJ, Mira A, Vila J, Marcos MA. Economic Impact of a New Rapid PCR Assay for Detecting Influenza Virus in an Emergency Department and Hospitalized Patients. PLoS One. 2016 Jan 20;11(1):e0146620. doi: 10.1371/journal.pone.0146620. eCollection 2016.
- Trabattoni E, Le V, Pilmis B, Pean de Ponfilly G, Caisso C, Couzigou C, Vidal B, Mizrahi A, Ganansia O, Le Monnier A, Lina B, Nguyen Van JC. Implementation of Alere i Influenza A & B point of care test for the diagnosis of influenza in an ED. Am J Emerg Med. 2018 Jun;36(6):916-921. doi: 10.1016/j.ajem.2017.10.046. Epub 2017 Oct 18.
- Brendish NJ, Malachira AK, Armstrong L, Houghton R, Aitken S, Nyimbili E, Ewings S, Lillie PJ, Clark TW. Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. Lancet Respir Med. 2017 May;5(5):401-411. doi: 10.1016/S2213-2600(17)30120-0. Epub 2017 Apr 6.
- Ho YII, Wong AH, Lai RWM. Comparison of the Cepheid Xpert Xpress Flu/RSV Assay to in-house Flu/RSV triplex real-time RT-PCR for rapid molecular detection of Influenza A, Influenza B and Respiratory Syncytial Virus in respiratory specimens. J Med Microbiol. 2018 Nov;67(11):1576-1580. doi: 10.1099/jmm.0.000841. Epub 2018 Sep 12.
- Banerjee D, Kanwar N, Hassan F, Essmyer C, Selvarangan R. Comparison of Six Sample-to-Answer Influenza A/B and Respiratory Syncytial Virus Nucleic Acid Amplification Assays Using Respiratory Specimens from Children. J Clin Microbiol. 2018 Oct 25;56(11):e00930-18. doi: 10.1128/JCM.00930-18. Print 2018 Nov.
- Bennett S, MacLean A, Gunson R. Verification of Cepheid Xpert Xpress Flu/RSV assay for use with gargle samples, sputa and endotracheal secretions. J Hosp Infect. 2019 Jan;101(1):114-115. doi: 10.1016/j.jhin.2018.07.016. Epub 2018 Jul 17. No abstract available.
- Popowitch EB, Miller MB. Comparison of the Xpert Flu/RSV XC and Xpress Flu/RSV Assays. J Clin Microbiol. 2018 Jul 26;56(8):e00278-18. doi: 10.1128/JCM.00278-18. Print 2018 Aug.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RBHP 2018 HENQUELL
- 2018-A02478-47 (Other Identifier: ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on Rapid diagnosis of influenza in the emergency medical service
-
University Hospital, GrenobleRecruitingAnkle Injuries | Treatment | Foot Injuries | DiagnosisFrance
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Conselho Nacional de Desenvolvimento Científico e TecnológicoUnknownHuman Immunodeficiency Virus | Human Immunodeficiency Virus Transmission | Diagnoses, Syndromes, and ConditionsBrazil
-
Kuopio University HospitalCompleted
-
University of RochesterAgency for Healthcare Research and Quality (AHRQ)CompletedAdverse Drug Event, Potential Adverse Drug Event, and Quality MeasuresUnited States
-
Hospices Civils de LyonCompletedViolent Aggressive Behavior | MediationFrance
-
The First Affiliated Hospital with Nanjing Medical...The First Affiliated Hospital of Soochow UniversityRecruitingthe Application of Artificial Intelligence in the Diagnosis of Prostate CancerChina
-
Sheba Medical CenterRecruiting
-
Beijing Haidian HospitalBeijing Fangshan District Liangxiang HospitalUnknownDiagnoses Disease | Acute Myocardial Infarction | Cardiac DiseaseChina
-
Hospices Civils de LyonCompletedOral Glucose Tolerance Test and Post Partum Diagnosis of Diabetes Mellitus, Type 2 (DT2 Post-Partum)Gestational DiabetesFrance
-
Eskisehir Osmangazi UniversityCompletedDiagnosis of Pleural DiseasesTurkey